Arrowstreet Capital Limited Partnership Purchases New Position in Pfizer Inc. (PFE)

Arrowstreet Capital Limited Partnership purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 31,900 shares of the biopharmaceutical company’s stock, valued at approximately $1,072,000.

Other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after buying an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Pfizer in the 2nd quarter worth about $268,389,000. Canada Pension Plan Investment Board boosted its holdings in Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its holdings in Pfizer by 42.1% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock worth $598,519,000 after buying an additional 5,281,314 shares during the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

Several research firms recently issued reports on PFE. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Barclays set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. Pfizer presently has a consensus rating of “Buy” and a consensus target price of $38.77.

Pfizer Inc. (NYSE PFE) traded up $0.47 on Tuesday, reaching $36.21. The company had a trading volume of 14,362,900 shares, compared to its average volume of 19,915,859. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $36.78. The firm has a market capitalization of $213,035.67, a PE ratio of 14.30, a PEG ratio of 2.52 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The firm’s quarterly revenue was up .9% on a year-over-year basis. equities analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date was Thursday, November 9th. Pfizer’s dividend payout ratio is presently 79.01%.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arrowstreet Capital Limited Partnership Purchases New Position in Pfizer Inc. (PFE)” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/12/arrowstreet-capital-limited-partnership-purchases-new-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply